AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.01 which represents a decrease of $-1.19 or -0.66% from the prior close of $179.2. The stock opened at $177.92 and touched a low of ...

This was the stock's second consecutive day of losses.

AbbVie Healthcare India Pvt. Ltd. found breaching UCPMP by sponsoring international trips for doctors, facing reprimand and ...

The stock's fall snapped a three-day winning streak.

Issued on behalf of Oncolytics Biotech Inc. Significant progress has also been made in pancreatic cancer, with plans for a registration-enabling study supported by collaborations with the Global ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $180 which represents a slight increase of $1.61 or 0.90% from the prior close of $178.39. The stock opened at $178.41 and touched a low ...

Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Explore more ...

the Indian arm of global biopharma major AbbVie Inc. The Committee, headed by Arunish Chawla, Secretary of DoP, reprimanded the company for unethical marketing practices sponsoring foreign vacations ...

Cerevel Therapeutics (Cerevel), a subsidiary of AbbVie Inc, is a clinical-stage biopharmaceutical company that develops therapies to treat neuroscience diseases. The company’s product pipeline ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...